FDA inspection

Divi's Laboratories Limited, Unit-1: FDA inspection ending Feb 14, 2008

FDA inspection 508452 · No Action Indicated (NAI) · Choutuppal

Key facts

Inspection ID 508452
Firm Divi's Laboratories Limited, Unit-1
FEI number 3003131136
Address Yadadri Bhuvanagiri District
City Choutuppal
Fiscal year 2008
Inspection end date Feb 14, 2008
Classification No Action Indicated (NAI)
Project area Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation|Generic Drug Evaluation|New Drug Evaluation
Product type Drugs

At a glance

  • None Citations
  • None Posted citations
  • No Warning letter followed
  • Yes Form FDA 483 issued
  • No Establishment inspection report (EIR) exists
  • 1–9 Inspections at this FEI

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About FDA inspections

FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.

Source: U.S. Food and Drug Administration (FDA), inspection classification data

Browse all FDA inspections